Drugs / ONVATILIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02671955 | Jan 2016 → Jan 2017 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONVATILIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298000 ↗ |
| Known as | JNJ-61610588 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02671955 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298000 ↗ |
| Route | Intravenous | “Participants will receive intravenous infusions of JNJ-61610588 until disease progression.” NCT02671955 ↗ |